{"id":"cross-over-to-osimertinib","safety":{"commonSideEffects":[{"rate":"55","effect":"Diarrhea"},{"rate":"35","effect":"Rash"},{"rate":"25","effect":"Dry skin"},{"rate":"20","effect":"Nausea"},{"rate":"15","effect":"Fatigue"},{"rate":"10","effect":"Stomatitis"},{"rate":"5","effect":"QTc prolongation"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Osimertinib selectively targets activating EGFR mutations (L858R, exon 19 deletions) and the resistant T790M mutation with high potency and specificity. By covalently binding to the ATP-binding pocket of mutant EGFR, it prevents autophosphorylation and downstream proliferation signals, while showing reduced activity against wild-type EGFR, thereby improving tolerability.","oneSentence":"Osimertinib is a third-generation EGFR tyrosine kinase inhibitor that irreversibly binds to and inhibits mutant EGFR, blocking downstream signaling in EGFR-mutant lung cancers.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:08:01.411Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"First-line treatment of metastatic non-small cell lung cancer with EGFR exon 19 deletions or L858R mutations"},{"name":"Treatment of metastatic EGFR T790M mutation-positive non-small cell lung cancer"},{"name":"Adjuvant treatment of stage IB-IIIA EGFR-mutant non-small cell lung cancer after resection"}]},"trialDetails":[{"nctId":"NCT02296125","phase":"PHASE3","title":"AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-12-03","conditions":"Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer","enrollment":674},{"nctId":"NCT06829459","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Glumetinib Combined With Osimertinib Mesylate Versus Platinum-based Doublet Chemotherapy in Non-Small Cell Lung Cancer Patients After Resistance to EGFR-TKIs","status":"RECRUITING","sponsor":"Shanghai JMT-Bio Inc.","startDate":"2025-04-03","conditions":"Non-Small Cell Lung Cancer","enrollment":350},{"nctId":"NCT02151981","phase":"PHASE3","title":"AZD9291 (Osimertinib) Versus Platinum-Based Doublet-Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-08-04","conditions":"Anticancer Treatment","enrollment":421},{"nctId":"NCT04479306","phase":"PHASE1","title":"Osimertinib in Combination With Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Mutant Stage IIIB or IV Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-06-18","conditions":"Recurrent Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8","enrollment":37},{"nctId":"NCT04816214","phase":"PHASE3","title":"Study Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in Adult Subjects With Non-small Cell Lung Cancers as Second Line Therapy","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-09-22","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":6}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Cross-over to Osimertinib","genericName":"Cross-over to Osimertinib","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Osimertinib is a third-generation EGFR tyrosine kinase inhibitor that irreversibly binds to and inhibits mutant EGFR, blocking downstream signaling in EGFR-mutant lung cancers. Used for First-line treatment of metastatic non-small cell lung cancer with EGFR exon 19 deletions or L858R mutations, Treatment of metastatic EGFR T790M mutation-positive non-small cell lung cancer, Adjuvant treatment of stage IB-IIIA EGFR-mutant non-small cell lung cancer after resection.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}